These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 12874017

  • 21. Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells.
    Couderc B, Zitvogel L, Douin-Echinard V, Djennane L, Tahara H, Favre G, Lotze MT, Robbins PD.
    Cancer Gene Ther; 1998; 5(3):163-75. PubMed ID: 9622100
    [Abstract] [Full Text] [Related]

  • 22. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen.
    Mutwiri G, Benjamin P, Soita H, Babiuk LA.
    Vaccine; 2008 May 23; 26(22):2680-8. PubMed ID: 18430493
    [Abstract] [Full Text] [Related]

  • 23. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens.
    Jahrsdörfer B, Hartmann G, Racila E, Jackson W, Mühlenhoff L, Meinhardt G, Endres S, Link BK, Krieg AM, Weiner GJ.
    J Leukoc Biol; 2001 Jan 23; 69(1):81-8. PubMed ID: 11200072
    [Abstract] [Full Text] [Related]

  • 24. Eradication of disseminated lymphomas with CpG-DNA activated T helper type 1 cells from nontransgenic mice.
    Egeter O, Mocikat R, Ghoreschi K, Dieckmann A, Röcken M.
    Cancer Res; 2000 Mar 15; 60(6):1515-20. PubMed ID: 10749115
    [Abstract] [Full Text] [Related]

  • 25. Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154.
    Mackey MF, Gunn JR, Ting PP, Kikutani H, Dranoff G, Noelle RJ, Barth RJ.
    Cancer Res; 1997 Jul 01; 57(13):2569-74. PubMed ID: 9205055
    [Abstract] [Full Text] [Related]

  • 26. Adjuvant activity of CpG oligodeoxynucleotides.
    Klinman DM.
    Int Rev Immunol; 2006 Jul 01; 25(3-4):135-54. PubMed ID: 16818369
    [Abstract] [Full Text] [Related]

  • 27. Fusion of CpG-ODN-stimulating dendritic cells with Lewis lung cancer cells can enhance anti-tumor immune responses.
    Du YC, Lin P, Zhang J, Lu YR, Ning QZ, Wang Q.
    Tissue Antigens; 2006 May 01; 67(5):368-76. PubMed ID: 16671943
    [Abstract] [Full Text] [Related]

  • 28. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy.
    VanOosten RL, Griffith TS.
    Cancer Res; 2007 Dec 15; 67(24):11980-90. PubMed ID: 18089829
    [Abstract] [Full Text] [Related]

  • 29. Immunogenetic therapy for B-cell malignancies.
    Kipps TJ, Chu P, Wierda WG.
    Semin Oncol; 2000 Dec 15; 27(6 Suppl 12):104-9. PubMed ID: 11225994
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. T cell activation following infection of primary follicle center lymphoma B cells with adenovirus encoding CD154.
    Cantwell MJ, Wierda WG, Lossos IS, Levy R, Kipps TJ.
    Leukemia; 2001 Sep 15; 15(9):1451-7. PubMed ID: 11516107
    [Abstract] [Full Text] [Related]

  • 32. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
    Suzuki Y, Wakita D, Chamoto K, Narita Y, Tsuji T, Takeshima T, Gyobu H, Kawarada Y, Kondo S, Akira S, Katoh H, Ikeda H, Nishimura T.
    Cancer Res; 2004 Dec 01; 64(23):8754-60. PubMed ID: 15574787
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Gene transfer of CD40-ligand to dendritic cells stimulates interferon-gamma production to induce growth arrest and apoptosis of tumor cells.
    Tomihara K, Kato K, Masuta Y, Nakamura K, Uchida H, Sasaki K, Tanaka T, Huang J, Hiratsuka H, Hamada H.
    Gene Ther; 2008 Feb 01; 15(3):203-13. PubMed ID: 17989706
    [Abstract] [Full Text] [Related]

  • 37. Complete rejection of a T-cell lymphoma due to synergism of T-cell receptor costimulatory molecules, CD80, CD40L, and CD40.
    Ruybal P, Gravisaco MJ, Barcala V, Escalada A, Di Sciullo P, Waldner C, Mongini C.
    Vaccine; 2008 Jan 30; 26(5):697-705. PubMed ID: 18155328
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Induction of autoantibody production but not autoimmune disease in HEL transgenic mice vaccinated with HEL in combination with CpG or control oligodeoxynucleotides.
    Wang Y, Krieg AM.
    Vaccine; 2004 Jun 30; 22(20):2641-50. PubMed ID: 15193390
    [Abstract] [Full Text] [Related]

  • 40. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope.
    Armstrong AC, Dermime S, Allinson CG, Bhattacharyya T, Mulryan K, Gonzalez KR, Stern PL, Hawkins RE.
    J Immunol; 2002 Apr 15; 168(8):3983-91. PubMed ID: 11937555
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.